Lucy Scientific Discovery, INC

Lucy Scientific Discovery Inc. will be delisted from the Nasdaq Capital Market effective July 1, 2024, and will begin trading on the OTC Markets Group platform.

Lucy Scientific Discovery Inc. is facing potential delisting from Nasdaq due to non-compliance with filing and stockholders' equity rules, with a hearing scheduled for June 25, 2024.

Lucy Scientific Discovery Inc. is facing delisting from the Nasdaq Capital Market due to insufficient stockholders' equity, and is appealing the decision.

Scott Reeves resigned from the Board of Directors of Lucy Scientific Discovery Inc. effective immediately on April 17, 2024.

Lucy Scientific Discovery, Inc. has terminated its amalgamation agreement with Bluesky Biologicals Inc. due to the failure of Bluesky to provide timely audited financial statements.

Lucy Scientific Discovery enacted a 1-for-10 reverse stock split to regain Nasdaq compliance and announced the expiration of its Chief Scientific Officer's contract.

Lucy Scientific Discovery Inc. reports a net loss of $4.6 million for the six months ended December 31, 2023, and secures convertible note financing.

Lucy Scientific Discovery Inc. has filed an amendment to its registration statement for the offer and resale of up to 7,361,688 common shares by selling stockholders, with potential proceeds from warrant exercises to be used for working capital.

Lucy Scientific Discovery Inc. has filed an amendment to its Form S-1 registration statement for the resale of up to 7,361,688 common shares by selling stockholders.

Lucy Scientific Discovery has filed a registration statement for the potential resale of up to 7,361,688 common shares by selling stockholders.